Overview

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Status:
Recruiting

Trial end date:
2026-10-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Phase:

Phase 3

Details

Lead Sponsor:

Bristol-Myers Squibb